摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]-N-[(2R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl]acetamide | 957117-95-2

中文名称
——
中文别名
——
英文名称
2-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]-N-[(2R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl]acetamide
英文别名
2-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4.5]decan-9-yl]-N-[(2R)-2'-oxospiro[1,3-dihydroindene-2,3'-1H-pyrrolo[2,3-b]pyridine]-5-yl]acetamide
2-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]-N-[(2R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl]acetamide化学式
CAS
957117-95-2
化学式
C32H31F2N5O3
mdl
——
分子量
571.627
InChiKey
GWAJYOYPXYSDHT-IOWSJCHKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    42
  • 可旋转键数:
    4
  • 环数:
    7.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    103
  • 氢给体数:
    3
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [11C]MK-4232
    摘要:
    降钙素基因相关肽(CGRP)是一种强效神经肽,其激动剂与外周的 CGRP 受体(CGRP-R)相互作用,可促进血管扩张、神经源性炎症和三叉神经血管感觉激活。这一过程与偏头痛的病因有关,临床开发中的 CGRP-R 拮抗剂已被证明能有效治疗人类偏头痛相关的疼痛。CGRP-R 在血管平滑肌、三叉神经感觉神经元和纤维的外周以及中枢神经系统中均有表达。然而,目前尚不清楚抑制中枢 CGRP-R 在缓解偏头痛疼痛方面发挥了什么作用。为此,CGRP-R 正电子发射断层扫描(PET)示踪剂 [11C]MK-4232 (2-[(8 R )-8-(3,5-difluorophenyl)-6,8-[6-11C]dimethyl-10-oxo-6,9-diazaspiro[4.5]癸烷-9-基]-N-[(2 R )-2′-氧代螺[1,3-二氢茚-2,3′-1 H -吡咯并[2,3- b ]吡啶]-5-基]乙酰胺)被发现并开发用于临床 PET 研究。在恒河猴和人体内,[11C]MK-4232 显示出快速的脑摄取,其脑区域分布与已知的 CGRP-R 分布一致。在静脉注射 CGRP-R 拮抗剂后,用 [11C]MK-4232 对猴子进行 PET 研究,验证了 [11C]MK-4232 检测 CGRP-R 占有率与药物血浆浓度成比例变化的能力。在人体 PET 研究中应用[11C]MK-4232 发现,在有效剂量(140 毫克 PO)下,telcagepant 只能达到较低的受体占用率。因此,偏头痛的疗效不太可能需要拮抗中枢 CGRP-R。不过,中枢 CGRP-R 的高度拮抗作用是否会带来额外的治疗效果,目前还不得而知。
    DOI:
    10.1124/jpet.113.206458
  • 作为产物:
    描述:
    tert-butyl [1-(3,5-difluorophenyl)-1-methyl-2-oxoethyl]carbamateN-甲基吗啉盐酸 、 sodium hydride 、 溶剂黄146 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 lithium hydroxide 作用下, 以 四氢呋喃甲醇5,5-dimethyl-1,3-cyclohexadiene乙醇乙酸乙酯N,N-二甲基甲酰胺 、 mineral oil 为溶剂, 反应 24.58h, 生成 2-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]-N-[(2R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl]acetamide
    参考文献:
    名称:
    [11C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor
    摘要:
    Rational modification of the potent calcitonin gene-related peptide (CGRP) receptor antagonist MK-3207 led to a series of analogues with enhanced CNS penetrance and a convenient chemical handle for introduction of a radiolabel. A number of C-11-tracers were synthesized and evaluated in vivo, leading to the identification of [C-11](8) ([C-11]MK-4232), the first positron emission tomography tracer for the CGRP receptor.
    DOI:
    10.1021/ml400199p
点击查看最新优质反应信息

文献信息

  • Substituted monocyclic CGRP receptor antagonists
    申请人:Wood Michael R.
    公开号:US20070265225A1
    公开(公告)日:2007-11-15
    Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , m, n, J, Q, R 4 , E a , E b , E c , R 6 , R 7 , R e , R f , R PG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    式I的化合物:(其中变量A1、A2、A3、A4、m、n、J、Q、R4、Ea、Eb、Ec、R6、R7、Re、Rf、RPG和Y如本文所述)是CGRP受体拮抗剂,可用于治疗或预防涉及CGRP的疾病,如偏头痛。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及CGRP的疾病中使用这些化合物和组合物。
  • In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [<sup>11</sup>C]MK-4232
    作者:Eric D. Hostetler、Aniket D. Joshi、Sandra Sanabria-Bohórquez、Hong Fan、Zhizhen Zeng、Mona Purcell、Liza Gantert、Kerry Riffel、Mangay Williams、Stacey O’Malley、Patricia Miller、Harold G. Selnick、Steven N. Gallicchio、Ian M. Bell、Christopher A. Salvatore、Stefanie A. Kane、Chi-Chung Li、Richard J. Hargreaves、Tjibbe de Groot、Guy Bormans、Anne Van Hecken、Inge Derdelinckx、Jan de Hoon、Tom Reynders、Ruben Declercq、Inge De Lepeleire、W. P. Kennedy、Rebecca Blanchard、Eugene E. Marcantonio、Cyrille Sur、Jacquelynn J. Cook、Koen Van Laere、Jeffrey L. Evelhoch
    DOI:10.1124/jpet.113.206458
    日期:2013.11
    Calcitonin gene-related peptide (CGRP) is a potent neuropeptide whose agonist interaction with the CGRP receptor (CGRP-R) in the periphery promotes vasodilation, neurogenic inflammation and trigeminovascular sensory activation. This process is implicated in the cause of migraine headaches, and CGRP-R antagonists in clinical development have proven effective in treating migraine-related pain in humans. CGRP-R is expressed on blood vessel smooth muscle and sensory trigeminal neurons and fibers in the periphery as well as in the central nervous system. However, it is not clear what role the inhibition of central CGRP-R plays in migraine pain relief. To this end, the CGRP-R positron emission tomography (PET) tracer [11C]MK-4232 (2-[(8 R )-8-(3,5-difluorophenyl)-6,8-[6-11C]dimethyl-10-oxo-6,9-diazaspiro[4.5]decan-9-yl]- N -[(2 R )-2′-oxospiro[1,3-dihydroindene-2,3′-1 H -pyrrolo[2,3- b ]pyridine]-5-yl]acetamide) was discovered and developed for use in clinical PET studies. In rhesus monkeys and humans, [11C]MK-4232 displayed rapid brain uptake and a regional brain distribution consistent with the known distribution of CGRP-R. Monkey PET studies with [11C]MK-4232 after intravenous dosing with CGRP-R antagonists validated the ability of [11C]MK-4232 to detect changes in CGRP-R occupancy in proportion to drug plasma concentration. Application of [11C]MK-4232 in human PET studies revealed that telcagepant achieved only low receptor occupancy at an efficacious dose (140 mg PO). Therefore, it is unlikely that antagonism of central CGRP-R is required for migraine efficacy. However, it is not known whether high central CGRP-R antagonism may provide additional therapeutic benefit.
    降钙素基因相关肽(CGRP)是一种强效神经肽,其激动剂与外周的 CGRP 受体(CGRP-R)相互作用,可促进血管扩张、神经源性炎症和三叉神经血管感觉激活。这一过程与偏头痛的病因有关,临床开发中的 CGRP-R 拮抗剂已被证明能有效治疗人类偏头痛相关的疼痛。CGRP-R 在血管平滑肌、三叉神经感觉神经元和纤维的外周以及中枢神经系统中均有表达。然而,目前尚不清楚抑制中枢 CGRP-R 在缓解偏头痛疼痛方面发挥了什么作用。为此,CGRP-R 正电子发射断层扫描(PET)示踪剂 [11C]MK-4232 (2-[(8 R )-8-(3,5-difluorophenyl)-6,8-[6-11C]dimethyl-10-oxo-6,9-diazaspiro[4.5]癸烷-9-基]-N-[(2 R )-2′-氧代螺[1,3-二氢茚-2,3′-1 H -吡咯并[2,3- b ]吡啶]-5-基]乙酰胺)被发现并开发用于临床 PET 研究。在恒河猴和人体内,[11C]MK-4232 显示出快速的脑摄取,其脑区域分布与已知的 CGRP-R 分布一致。在静脉注射 CGRP-R 拮抗剂后,用 [11C]MK-4232 对猴子进行 PET 研究,验证了 [11C]MK-4232 检测 CGRP-R 占有率与药物血浆浓度成比例变化的能力。在人体 PET 研究中应用[11C]MK-4232 发现,在有效剂量(140 毫克 PO)下,telcagepant 只能达到较低的受体占用率。因此,偏头痛的疗效不太可能需要拮抗中枢 CGRP-R。不过,中枢 CGRP-R 的高度拮抗作用是否会带来额外的治疗效果,目前还不得而知。
  • RADIOLABELED CGRP ANTAGONISTS
    申请人:Bell Ian M.
    公开号:US20120121508A1
    公开(公告)日:2012-05-17
    The present invention is directed to radiolabeled CGRP receptor antagonists which are useful for the quantitative imaging of CGRP receptors in mammals.
    本发明涉及用于哺乳动物中CGRP受体定量成像的放射性标记的CGRP受体拮抗剂。
  • US7629338B2
    申请人:——
    公开号:US7629338B2
    公开(公告)日:2009-12-08
  • [<sup>11</sup>C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor
    作者:Ian M. Bell、Steven N. Gallicchio、Craig A. Stump、Joseph G. Bruno、Hong Fan、Liza T. Gantert、Eric D. Hostetler、Amanda L. Kemmerer、Melody McWherter、Eric L. Moore、Scott D. Mosser、Mona L. Purcell、Kerry Riffel、Christopher A. Salvatore、Sandra Sanabria-Bohórquez、Donnette D. Staas、Rebecca B. White、Mangay Williams、C. Blair Zartman、Jacquelynn J. Cook、Richard J. Hargreaves、Stefanie A. Kane、Samuel L. Graham、Harold G. Selnick
    DOI:10.1021/ml400199p
    日期:2013.9.12
    Rational modification of the potent calcitonin gene-related peptide (CGRP) receptor antagonist MK-3207 led to a series of analogues with enhanced CNS penetrance and a convenient chemical handle for introduction of a radiolabel. A number of C-11-tracers were synthesized and evaluated in vivo, leading to the identification of [C-11](8) ([C-11]MK-4232), the first positron emission tomography tracer for the CGRP receptor.
查看更多